emeis Société anonyme

LSE:0NEX Stock Report

Market Cap: €957.8m

emeis Société anonyme Valuation

Is 0NEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0NEX (€5.88) is trading below our estimate of fair value (€36.07)

Significantly Below Fair Value: 0NEX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NEX?

Key metric: As 0NEX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0NEX. This is calculated by dividing 0NEX's market cap by their current earnings.
What is 0NEX's PE Ratio?
PE Ratio0.7x
Earnings€1.47b
Market Cap€957.82m

Price to Earnings Ratio vs Peers

How does 0NEX's PE Ratio compare to its peers?

The above table shows the PE ratio for 0NEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.4x
CVSG CVS Group
22.8x15.5%UK£592.6m
SPI Spire Healthcare Group
32x26.9%UK£906.5m
MDC Mediclinic International
21.9x10.7%UK£3.7b
CRW Craneware
80.9x24.3%UK£752.9m
0NEX emeis Société anonyme
0.7x-92.5%€957.8m

Price-To-Earnings vs Peers: 0NEX is good value based on its Price-To-Earnings Ratio (0.7x) compared to the peer average (45.2x).


Price to Earnings Ratio vs Industry

How does 0NEX's PE Ratio compare vs other companies in the European Healthcare Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.18.2x23.3%
0NEX emeis Société anonyme
0.7x-92.5%US$998.66m
0NEX 0.7xIndustry Avg. 18.2xNo. of Companies9PE01020304050+
4 CompaniesEstimated GrowthMarket Cap
Industry Avg.18.2x23.3%
0NEX emeis Société anonyme
0.7x-92.5%US$998.66m
No more companies

Price-To-Earnings vs Industry: 0NEX is good value based on its Price-To-Earnings Ratio (0.7x) compared to the European Healthcare industry average (18.2x).


Price to Earnings Ratio vs Fair Ratio

What is 0NEX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NEX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.7x
Fair PE Ratio4.8x

Price-To-Earnings vs Fair Ratio: 0NEX is good value based on its Price-To-Earnings Ratio (0.7x) compared to the estimated Fair Price-To-Earnings Ratio (4.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NEX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.35
€10.53
+96.6%
28.6%€14.00€7.20n/a4
Dec ’25€5.83
€10.53
+80.6%
28.6%€14.00€7.20n/a4
Nov ’25€6.31
€11.63
+84.4%
23.0%€14.00€7.90n/a3
Oct ’25€5.51
€11,633.33
+211,223.0%
23.0%€14,000.00€7,900.00n/a3
Sep ’25€9.16
€11,633.33
+126,872.2%
23.0%€14,000.00€7,900.00n/a3
Aug ’25€10.29
€11,633.33
+112,919.8%
23.0%€14,000.00€7,900.00n/a3
Jul ’25€12.38
€11,725.00
+94,600.9%
24.7%€15,000.00€7,900.00n/a4
Jun ’25€12.52
€11,725.00
+93,543.9%
24.7%€15,000.00€7,900.00n/a4
May ’25€13.20
€10,975.00
+83,016.0%
20.7%€14,000.00€7,900.00n/a4
Apr ’25€10.75
€6,230.00
+57,871.3%
95.5%€14,000.00€20.00n/a4
Mar ’25€12.94
€3,640.00
+28,029.8%
123.9%€10,000.00€20.00n/a3
Feb ’25€13.80
€2,737.50
+19,737.0%
153.7%€10,000.00€20.00n/a4
Jan ’25€16.81
€2,737.50
+16,184.9%
153.7%€10,000.00€20.00n/a4
Dec ’24€17.42
€2,737.50
+15,614.7%
153.7%€10,000.00€20.00€5.834
Nov ’24€898.71
€3,910.00
+335.1%
117.1%€10,000.00€20.00€6.315
Oct ’24€1,472.11
€3,909.99
+165.6%
117.1%€10,000.00€20.00€5.515
Sep ’24€1,702.83
€3,909.99
+129.6%
117.1%€10,000.00€20.00€9.165
Aug ’24€1,750.07
€3,939.99
+125.1%
115.6%€10,000.00€30.02€10.295
Jul ’24€1,904.67
€4,005.97
+110.3%
112.3%€10,000.00€170.01€12.385
Jun ’24€1,858.75
€4,917.48
+164.6%
93.5%€10,000.00€170.01€12.524
May ’24€2,656.67
€5,561.99
+109.4%
76.7%€10,000.00€289.94€13.205
Apr ’24€2,070.99
€5,601.65
+170.5%
69.5%€10,000.00€289.94€10.756
Mar ’24€2,495.44
€10,944.27
+338.6%
124.0%€43,000.00€289.94€12.947
Feb ’24€6,167.13
€13,688.58
+122.0%
91.1%€43,000.00€4,000.00€13.807
Jan ’24€6,204.00
€17,165.00
+176.7%
86.5%€43,000.00€4,000.00€16.818
Dec ’23€6,756.76
€17,415.00
+157.7%
84.1%€43,000.00€5,799.97€17.428

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 21:22
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

emeis Société anonyme is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lionel PellicerAlphaValue
Stéphan DubosqArkeon Finance
Beatrice AllenBerenberg